Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade) [Seeking Alpha]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Seeking Alpha
Summary Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million by June 30, 2024, ensuring a cash runway into 2026, according to Rhythm's projections. Imcivree is currently undergoing a Phase 3 trial for hypothalamic obesity, with results expected in 1H 2025, crucial for its potential blockbuster status. RYTM stock is a speculative "buy" based on the potential of Imcivree in treating hypothalamic obesity, though there are significant risks if the trial fails. libre de droit/iStock via Getty Images Introduction Rhythm Pharmaceuticals NASDAQ: RYTM ) stock has risen nearly 12% since my rating upgrade to "hold" in May, following their Q1 results. Remember that Rhythm is a commercial-stage biotechnology company that markets Imcivree , its lead asset, to treat obesity caused by rare genetic disorders such as POMC, PCSK1, or LEPR defic
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $64.00 price target on the stock.MarketBeat
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $64.00 price target on the stock.MarketBeat
- Rhythm Pharmaceuticals Announces New Employment Inducement GrantsGlobeNewswire
- Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 8/6/24 - Beat
RYTM
Sec Filings
- 9/19/24 - Form 8-K
- 9/19/24 - Form 4
- 9/17/24 - Form 144
- RYTM's page on the SEC website